Primary study · included by 1 review
An osteoimmunomodulatory Ca2+/Zn2+-doped scaffold promotes M2 macrophage polarization via the src-mediated chemoking signaling pathway to enhance osteoinduction
K. Wang 2024 · Wang Kai, Jiang Kai, Luo Chuan, et al. · Composites Part B: Engineering · 2024
Included by
| Outcome this study informs | Pooled effect | Evidence | Certainty |
|---|---|---|---|
Bone regeneration (BV/TV, %) at 1-2 months (middle stage) Polycaprolactone (PCL)-only scaffold vs Empty defect · 1-2 months (middle) | QM = 0.019, df = 1, p = 0.891, R2 = 0% | 27 studies | GRADE not reported |
Bone regeneration (BV/TV, %) at one month (early stage) Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month) | QM = 9.509, df = 3, p = 0.023, R2 = 28.8% | 20 studies | GRADE not reported |
Bone regeneration (BV/TV, %) at one month (early stage) Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month) | Meta-regression beta (difference in MD, %) 0.853 [-4.49, 6.195] | 20 studies | GRADE not reported |
Bone regeneration (BV/TV, %) at one month (early stage) Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month) | MD 1.68 [0.34, 3.03] | 18 studies · 194 participants | GRADE not reported |
Bone regeneration (BV/TV, %) at 1-2 months (middle stage) Polycaprolactone (PCL)-only scaffold vs Empty defect · 1-2 months (middle) | QM = 0.148, df = 1, p = 0.701, R2 = 0% | 27 studies | GRADE not reported |
Bone regeneration (BV/TV, %) at one month (early stage) Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month) | Meta-regression beta (difference in MD, %) -4.258 [-8.216, -0.3] | 20 studies | GRADE not reported |
Bone regeneration (BV/TV, %) at 1-2 months (middle stage) Polycaprolactone (PCL)-only scaffold vs Empty defect · 1-2 months (middle) | QM = 3.742, df = 2, p = 0.154, R2 = 6.4% | 27 studies | GRADE not reported |
Bone regeneration (BV/TV, %) at one month (early stage) Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month) | QM = 0.703, df = 1, p = 0.402, R2 = 0% | 20 studies | GRADE not reported |
Bone regeneration (BV/TV, %) at 1-2 months (middle stage) Polycaprolactone (PCL)-only scaffold vs Empty defect · 1-2 months (middle) | MD 5.6 [3.48, 7.72] | 25 studies · 260 participants | GRADE not reported |
Bone regeneration (BV/TV, %) at 1-2 months (middle stage) Polycaprolactone (PCL)-only scaffold vs Empty defect · 1-2 months (middle) | Meta-regression beta (difference in MD, %) 10.748 [-0.505, 22.001] | 27 studies | GRADE not reported |
Bone regeneration (BV/TV, %) at one month (early stage) Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month) | Meta-regression beta (difference in MD, %) -6.987 [-12.867, -1.108] | 20 studies | GRADE not reported |
Bone regeneration (BV/TV, %) at 1-2 months (middle stage) Polycaprolactone (PCL)-only scaffold vs Empty defect · 1-2 months (middle) | Meta-regression beta (difference in MD, %) 1.677 [-3.37, 6.723] | 27 studies | GRADE not reported |
Bone regeneration (BV/TV, %) at one month (early stage) Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month) | QM = 0.334, df = 1, p = 0.563, R2 = 0% | 20 studies | GRADE not reported |
1 including review in total.